Search Results
Nov 07, 2025, 08:00 ET PRM Pharma Announces Nationwide Availability of HemiClor® (Chlorthalidone) 12.5 mg: The First FDA-Approved Low-Dose Chlorthalidone Tablet Aligned With Hypertension Guidelines
1991;265(1):3255-3264. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation,
More news about: PRM Pharma, LLC
Nov 07, 2025, 08:00 ET Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025
Company is also advancing efforts to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh, is based in Edinburgh
More news about: Resolution Therapeutics
Nov 07, 2025, 08:00 ET AAM Reports Third Quarter 2025 Financial Results
$5.8 - $5.9 billion vs. $5.75 - $5.95 billion prior. AAM is targeting Adjusted EBITDA in the range of $710 - $745 million vs. $695 - $745 million prior. AAM is targeting Adjusted free cash flow in the range of $180 - $210 million vs. $175 - $215 million
More news about: American Axle & Manufacturing Holdings, Inc.
Nov 07, 2025, 07:55 ET KOPPERS REPORTS THIRD QUARTER 2025 RESULTS
Million vs. $554.3 Million in Prior Year Quarter Net income attributable to Koppers of $23.8 Million vs. $22.8 Million in Prior Year Quarter Diluted EPS of $1.17 vs. $1.09 in Prior Year Quarter Adjusted EPS of $1.21 vs. $1.37
More news about: KOPPERS HOLDINGS INC.
Nov 07, 2025, 07:42 ET Michter's brengt de release uit van de 20 Year Bourbon
is gemaakt." De proof van deze 2025 release is 114,2 (alcoholpercentage 57,1%) en de adviesprijs voor een fles van 750 ml in de VS is $1.200. "Ons productieteam is bijzonder trots oom zo'n speciale whiskey aan te bieden. Het rijpen van deze vaten vergt veel
More news about: Michter's Distillery
Nov 07, 2025, 07:30 ET TDS reports third quarter 2025 results
2025 vs. 2024
More news about: Telephone and Data Systems, Inc.
Nov 07, 2025, 07:30 ET Array reports third quarter 2025 results
2025 vs. 2024
More news about: Array Digital Infrastructure, Inc.
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
treatment was delayed for patients receiving DARZALEX FASPRO® compared to active monitoring, with median time to first treatment NR vs 50.2 months for the active monitoring group (HR, 0.46; 95 percent CI, 0.33-0.62).1 "DARZALEX FASPRO is a foundational
More news about: Johnson & Johnson
Nov 06, 2025, 16:36 ET CON EDISON REPORTS 2025 THIRD QUARTER EARNINGS
Variation for the Three Months Ended September 30, 2025 vs. 2024
More news about: Consolidated Edison, Inc.
Nov 06, 2025, 16:18 ET Huntsman Announces Third Quarter 2025 Earnings
September 30, 2025 vs. 2024
More news about: Huntsman Corporation
Nov 06, 2025, 16:15 ET TOPGOLF CALLAWAY BRANDS ANNOUNCES THIRD QUARTER 2025 RESULTS
vs. 2024(1)
More news about: Topgolf Callaway Brands Corp.
Nov 06, 2025, 16:15 ET EOG Resources Reports Third Quarter 2025 Results
Third Quarter 2025 Results vs Guidance
More news about: EOG Resources, Inc.
Nov 06, 2025, 16:15 ET Brookdale Announces Third Quarter 2025 Results and Increases Adjusted EBITDA Annual Guidance
OVERVIEW OF RESULTS: 3Q 2025 vs 3Q 2024 Resident fees: The
More news about: Brookdale Senior Living Inc.
Nov 06, 2025, 16:10 ET Metallus Announces Third-Quarter 2025 Results
2024 3Q vs. 2025 3Q
More news about: Metallus Inc.
Nov 06, 2025, 16:05 ET Astrana Health, Inc. Reports Third Quarter 2025 Results
% change vs. prior year quarter
More news about: Astrana Health, Inc.
Nov 06, 2025, 16:00 ET Curis Provides Third Quarter 2025 Business Update
combination therapy in current and/or potential new studies; any statements concerning the design of a head-to-head registrational trial of emavusertib vs. gilteritinib in R/R AML, and the design of a Phase 1/2 study in frontline high-risk MDS (hrMDS) in combination with azacitidine; statements regarding
More news about: Curis, Inc.
Nov 06, 2025, 11:00 ET Mockly Rebrand Reinvents the Non-Alcohol Drinking Experience, New Orleans Style
Mockly is also returning to its original 8.4 oz can - a deliberate move to establish themselves as cocktail-adjacent (traditionally 8 oz) vs. soda or seltzer (traditionally 12 oz). In addition, these smaller cans mean less sugar and fewer calories.
More news about: Mockly
Nov 06, 2025, 10:02 ET Universal "AI for Health" Summit Draws Health Leaders and Innovators for Two Days of Education to Help Shape the Future of Healthcare
Technologies: Building What's Next in Health AI Policies and Guardrails for AI in Healthcare Potentials vs. Pitfalls: The Pros and Cons of Implementation of AI in Healthcare Of great interest at this year's summit
More news about: MedStar Health
Nov 06, 2025, 09:15 ET IQST - IQSTEL Reports Explosive Q3 Growth With $102.8 Million Net Revenue, Up 42% vs. Q2
multimedia:https://www.prnewswire.com/news-releases/iqst--iqstel-reports-explosive-q3-growth-with-102-8-million-net-revenue-up-42-vs-q2--302606964.html
More news about: iQSTEL
Nov 06, 2025, 08:30 ET Datassential Releases 2026 Food and Beverage Trends Report
"This year's report captures a pivotal moment where trends are starting increasingly at retail (vs. restaurants), fiber is poised to overtake protein as the next big health trend, and animal meat is making a comeback," said Jaclyn Marks, Senior Publications
More news about: Datassential
Nov 06, 2025, 08:00 ET Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
A Randomized Phase 2 Non-Inferiority Trial of (Z)-Endoxifen + Goserelin vs Exemestane + Goserelin as Neoadjuvant Treatment forPremenopausal Women with ER+/HER2- Breast Cancer (EVANGELINE)
More news about: Atossa Therapeutics Inc
Nov 06, 2025, 07:24 ET DCW Limited Q2 FY26 EBITDA Surges 51% YoY; H1 PAT Rises 360%, Driven By Specialty Segment Growth and Alternate Energy-Substitution Gains
Q2 Revenue from Operations grew by 10.33% YoY (₹539.21 crore vs. ₹488.74 crore) and 13.40% quarter-on-quarter (QoQ) (₹539.21 crore vs. ₹475.50 crore). Q2 EBITDA increased significantly by 51.17%
More news about: DCW Limited
Nov 06, 2025, 07:05 ET Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
p-value vs. placebo4
More news about: Viking Therapeutics, Inc.
Nov 06, 2025, 06:30 ET BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
Change vs. prior year (basis points)
More news about: BD (Becton, Dickinson and Company)
Nov 06, 2025, 06:00 ET DuPont Reports Third Quarter 2025 Results; Announces Plans to Return Cash to Shareholders
vs. 3Q'24
More news about: DuPont